We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Deleting the Dicer DNA-Repair Enzyme Increases Sensitivity of Cancer Cells to Chemotherapy

By LabMedica International staff writers
Posted on 12 Jan 2016
Blocking the activity of the enzyme Dicer in rapidly growing cancer cells prevents them from correcting DNA damage, which renders them more sensitive to the action of chemotherapeutic drugs.

Dicer, also known as endoribonuclease Dicer or helicase with RNase motif, is an enzyme that in humans is encoded by the DICER1 gene. More...
Being part of the RNase III family, Dicer cleaves double-stranded RNA (dsRNA) and pre-microRNA (pre-miRNA) into short double-stranded RNA fragments called small interfering RNA and microRNA, respectively. In 2012 it was found that in addition to its effects on RNA, Dicer had a direct role of in repairing DNA damage.

To expand on findings linking Dicer to DNA repair, investigators at the University of North Carolina (Chapel Hill, USA) deleted Dicer in preclinical mouse models of medulloblastoma, a common type of brain cancer in children, and from the normal, rapidly dividing developing brain cells in the mouse cerebellum.

They reported in the December 31, 2015, online edition of the journal Cell Reports that deletion of Dicer in the developing mouse cerebellum resulted in the accumulation of DNA damage leading to cerebellar progenitor degeneration. Dicer deficiency also resulted in DNA damage and death in other rapidly dividing cells including embryonic stem cells and the malignant cerebellar progenitors in the mouse model of medulloblastoma. In the Dicer-deficient medulloblastoma mice, the tumor load was lower than in control animals, and the cancer cells were more sensitive to chemotherapy.

“This is the first time that the specific function of Dicer for DNA damage has been looked at in the context of the developing brain or even in brain tumors, despite that the fact that the protein has been extensively studied,” said senior author Dr. Mohanish Deshmukh, professor of cell biology and physiology at the University of North Carolina. “We have found that targeting Dicer could be an effective therapy to either prevent cancer development or to actually sensitize tumors to chemotherapy. We are excited about these results because of the implication that Dicer inhibitors could be developed as a potential therapy for treating rapidly dividing tumors like medulloblastoma.”

Related Links:

University of North Carolina 



Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.